Skip to content
Pharma Observatory a Scientist.com platform

Organization (Hospital)

Ohio State University Comprehensive Cancer Center

ClinicalTrials.gov lists Ohio State University Comprehensive Cancer Center as lead sponsor of 374 trials. It has 339 active development programs and 114 approved assets.

US Hospital
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

39 0 1994 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 39 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 35 in 2026 and about 26 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 39 already registered with a 2026 start date: at the cutoff, 11 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts. 1 trial is registered to start in 2027 or later.

This page covers Ohio State University Comprehensive Cancer Center: 374 lead-sponsored trials and 0 legal-entity registrations.

Get the Ohio State University Comprehensive Cancer Center report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (178)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Breast Neoplasms 68
Lung Neoplasms 33
Colorectal Neoplasms 26
Head and Neck Neoplasms 23
Lymphoma 21

Trials by start year as sponsor or collaborator (31)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 39
2025 21
2024 17
2023 26
2022 23
2021 26
2020 19
2019 11
2018 17
2017 15

Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 56 trials still running at the 2026-10-09 snapshot; 39 of 56 predicted trials reach the 36-month horizon; registered median of 30 months across 250 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (339)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
DEXAMETHASONE Breast Neoplasms Phase 2/3 1
Famotidine Breast Carcinoma In Situ Phase 2/3 1
Famotidine Breast Neoplasms Phase 2/3 1
DEXAMETHASONE Breast Carcinoma In Situ Phase 2/3 1
Cimetidine Breast Carcinoma In Situ Phase 2/3 1

Approved assets (114)

Shown in this order: max phase first.

Approved assets
Drug Trials
Nicotine Oral Pouch 6
Usual brand cigar 1
Normal nicotine content cigar 1
Arm I (MEP) 1
Reduced Nicotine Content Cigars 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
38% hit target (n=154) 47% on time (n=146)

Journals published in (160)

Shown in this order: most published in first.

Journals published in
Journal Publications
Cancer 11
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 10
Psycho-oncology 7
The New England journal of medicine 7
PloS one 6

Organization relationships (33)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Government of the United States of America Co sponsors trial with 11
Bristol Myers Squibb Co Co sponsors trial with 5
Roche (Switzerland) Co sponsors trial with 4
Bayer (Germany) Co sponsors trial with 3
The University of Texas System Co sponsors trial with 2

Latest dated events (383)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-02-15 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-11-25 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (459)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
AFP Trial sponsor Named in trial inclusion criteria
AFP Trial sponsor Named in trial inclusion criteria
AIM2 Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria

Biomarkers this organization publishes on (847)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
TP53 31
BTK 29
ERBB2 25
EGFR 22
PDCD1 21

On Scientist.com

Ohio State University Comprehensive Cancer Center is listed as a research supplier in the Scientist.com network.

The Clinical Trials Office Shared Resource provides a centralized resource of comprehensive management services for the OSUCCC investigators to conduct successful clinical trials in a methodologically sound, expedient and cost-effective manner.

Website
cancer.osu.edu/research/cancerresearch/sharedresources/cto/services/pages/index.aspx

Source: Scientist.com supplier network

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.

Work with Comprehensive Cancer Center, The Ohio State University on Scientist.com

For prices, more details, or to contact Comprehensive Cancer Center, The Ohio State University, visit Scientist.com.

Sign in to Scientist.com to open this supplier in your organization's marketplace.